WSO, you've gotten me this far, now help me close this deal. I began my tenure as a lowly monkey about two and a half years ago, and you've all helped pull a non-target student-athlete up into the ranks.
I'm sitting on an exploding offer to join the M&A team at a small boutique that will expire in five days. Once those five days are up, the firm will re-open recruiting to other candidates. The problem is, if I had until the end of the month, I would be able to finish my recruiting processes with three other firms, two of which I view as having a reasonable probability of being successful. I've been able to expedite the timeline of the undecided firms but was unable to extend the deadline on the exploding offer; therefore, it is unlikely I receive a second offer within five days.
One of these positions is with a well-known turnaround / consulting firm, and the other is with an MM investment bank specializing in Rx. The third option is with a BB in New York, but I don't weigh that one quite as heavily since I am coming out of a non-target and have no prior connections there (somehow my application got selected for first-round interviews with two different groups).
The question is if my goal is to work in IB/PE long-term, which of these routes would be the best strategic starting point for a career? Going with the turn-around/consulting firm offers a more substantial internal reach within the firm to potentially move to a more desirable group, while taking the bird in hand guarantees solid M&A experience, although at a lesser known firm. Personally, all else equal, I find the Rx focused bank to be the most exciting opportunity. However, the risk of forgoing the present offer is that no offers fill its place. Any/all input is appreciated.